Supplemental table 2 Quality appraisal of prevalence studies reporting prevalence of pain

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | Was the sample frame appropriate to address the target population? | Were study participants sampled in an appropriate way? | Was the sample size adequate? | Were the study subjects and the setting described in detail? | Was the data analysis conducted with sufficient coverage of the identified sample? | Were valid methods used for the identification of the condition? | Was the condition measured in a standard, reliable way for all participants? | Was there appropriate statistical analysis? | Was the response rate adequate, and if not, was the low response rate managed appropriately? |
| Asuman et al.13 | yes | yes | yes | no | yes | unclear | unclear | no | yes |
| Benner et al. 78 | yes | yes | no | yes | yes | unclear | yes | no | yes |
| Bourelle et al.20 | no | unclear | no | no | yes | unclear | unclear | yes | yes |
| Dauvergne et al.79 | yes | yes | yes | no | unclear | no | unclear | no | no |
| de Albuquerque et al.80 | no | yes | no | no | yes | unclear | unclear | yes | unclear |
| du Toit et al.26 | no | no | no | no | yes | unclear | yes | no | yes |
| Eken et al.27 | no | yes | no | no | yes | unclear | unclear | no | unclear |
| Engel et al.77 | no | yes | no | yes | yes | unclear | unclear | yes | unclear |
| Flanigan et al.53 | yes | yes | no | no | no | unclear | yes | no | unclear |
| Frank and De Souza21 | no | no | no | no | unclear | no | unclear | yes | unclear |
| Gallien et al.22 | unclear | yes | yes | no | unclear | unclear | yes | yes | yes |
| Garca Jalon et al.81 | yes | yes | yes | yes | yes | yes | yes | no | yes |
| Gotze et al.82 | no | yes | no | no | no | yes | yes | yes | no |
| Hilberink et al.75 | no | yes | no | yes | yes | unclear | yes | no | yes |
| Hirsh et al.71 | no | no | no | yes | unclear | unclear | unclear | no | no |
| Hung et al.73 | yes | yes | yes | no | yes | no | yes | no | unclear |
| İçağasıoğlu et al.43 | yes | yes | no | yes | yes | unclear | unclear | yes | unclear |
| Jacobson et al.35 | no | yes | no | no | yes | yes | yes | no | yes |
| Jahnsen e al.32 | no | yes | yes | yes | yes | unclear | yes | yes | no |
| Jarl et al.4 | yes | yes | yes | no | yes | unclear | yes | yes | yes |
| Jonsson et al.34 | yes | unclear | no | yes | unclear | unclear | yes | yes | unclear |
| Langerak et al.24 | no | yes | no | no | yes | unclear | yes | no | yes |
| Lundkvist Josenby and Westbom56 | no | yes | no | yes | yes | unclear | yes | no | unclear |
| Murphy et al.72 | yes | no | no | no | yes | unclear | yes | yes | unclear |
| Noonan et al.54 | no | unclear | no | no | yes | unclear | yes | no | yes |
| Noonan et al.54 | no | unclear | no | no | yes | unclear | yes | no | yes |
| Opheim et al.31 | no | unclear | no | yes | unclear | unclear | yes | yes | yes |
| Opheim et al.44 | no | unclear | no | yes | yes | unclear | yes | yes | yes |
| Park and Kim46 | unclear | yes | no | no | no | unclear | unclear | no | no |
| Patatoukas et al.76 | no | yes | no | no | unclear | unclear | unclear | yes | yes |
| Peterson et al.38 | unclear | yes | no | no | no | yes | yes | yes | unclear |
| Peterson et al.39 | yes | yes | yes | no | yes | unclear | yes | yes | yes |
| Rodby-Bousquet et al.42 | yes | yes | no | no | unclear | unclear | yes | yes | yes |
| Rodby-Bousquet et al.10 | yes | yes | yes | yes | yes | unclear | yes | yes | yes |
| Salie et al.74 | no | no | no | no | unclear | yes | yes | no | unclear |
| Sandstrom et al.47 | yes | yes | no | no | yes | unclear | yes | yes | no |
| Sarmiento et al.30 | unclear | yes | no | no | yes | unclear | yes | no | yes |
| Schmidt et al.37 | no | yes | no | no | yes | unclear | yes | unclear | unclear |
| Shrader et al.33 | no | yes | no | no | yes | yes | yes | no | no |
| Sienko48 | yes | yes | no | no | yes | unclear | yes | no | no |
| Tedroff et al.28 | no | yes | no | no | yes | unclear | Unclear | yes | yes |
| Terjesen et al.51 | yes | yes | no | no | yes | unclear | unclear | unclear | no |
| Thorpe et al.84 | no | yes | yes | no | yes | yes | yes | yes | yes |
| Turk et al.50 | no | yes | no | yes | yes | unclear | yes | yes | unclear |
| Van Der Slot et al.29 | no | yes | no | yes | yes | unclear | yes | yes | no |
| van Gorp et al.40 | no | unclear | no | yes | yes | yes | yes | no | no |
| Veerbeek et al.25 | no | yes | no | no | yes | unclear | yes | no | yes |
| Vidart et al.6 | yes | yes | no | yes | yes | unclear | yes | no | yes |
| Whitney et al.12 | yes | yes | yes | no | yes | unclear | yes | no | unclear |

**REFERENCES**

78. Benner JL, Hilberink SR, Veenis T, Stam HJ, van der Slot WM, Roebroeck ME. Long-Term Deterioration of Perceived Health and Functioning in Adults With Cerebral Palsy. Arch Phys Med Rehabil. 2017;98(11):2196-205.

79. Dauvergne F, Eon Y, Gallien P, Bouric S, Duruflé-Tapin A, Cambla N, Nicolas B. Disabilities, access to medical care, and way of life of adults with cerebral palsy. APIB study: first results. Ann Readapt Med Phys. 2007;50(1):20-27. doi:10.1016/j.annrmp.2006.06.008.

80. Botura C de A, Ames FQ, Botura AC de A, Bersani-Amado LE, Bardini AVSL, Cuman RK. Pain symptoms in patients with severe cerebral palsy: Prevalence among patients with higher degree of locomotor impairment. Trop J Pharm Res 2017;16(6):1431-6.

81. García Jalón EG, Maguire A, Perra O, Gavin A, O'Reilly D, Thurston A. Data linkage and pain medication in people with cerebral palsy: A cross-sectional study. Dev Med Child Neurol 2021;63(9):1085-92.

82. Marco Götze, MD, Andreas Geisbüsch, MD, Mirjam Thielen, MD, Leonhard Döderlein, MD, Sebastian I. Wolf, Thomas Dreher, MD, and Cornelia Putz, MD. Pain in Adults With Cerebral Palsy After Single-Event Multilevel Surgery.Am J Phys Med Rehabil 2022;101:119–123.

84. Thorpe D, Gannotti M, Peterson MD, Wang C-H, Freburger J. Musculoskeletal diagnoses, comorbidities, and physical and occupational therapy use among older adults with and without cerebral palsy. Disabil Health J 2021;14(2):101109.